Ultragenyx Pharmaceutical Inc. (RARE)
RARE moved a median of +0.12% 30 minutes after news, and +0.01% by the close. How RARE actually reacts to news — the realized, point-in-time move the market made, measured across 967 labeled events over the last three years with zero look-ahead.
RARE’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.05% | 55% | 956 |
| 30-min | +0.12% | 56% | 960 |
| 60-min | +0.05% | 52% | 960 |
| to close | +0.01% | 50% | 958 |
| Middle 50% of RARE reactions | -0.66% to +1.00% |
|---|---|
| Median reaction (30-min) | +0.12% |
| Measured reactions | 967 |
Half of all Ultragenyx Pharmaceutical Inc. news events land between -0.66% and +1.00% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How RARE reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 28 | +2.60% | 79% | +3.17% |
| Coverage initiations | 13 | -0.90% | 39% | -3.21% |
| Rating reiterations | 143 | +0.20% | 59% | +0.27% |
| Price-target raises | 38 | +0.02% | 53% | +0.06% |
| Price-target cuts | 41 | +0.61% | 66% | +0.61% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how RARE ranks against every other measured name →
That’s how RARE usually reacts — get an email when it moves on news →Email me when RARE moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to RARE's baseline. Nothing else.
Recent RARE events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Ultragenyx Pharmaceutica For: Oct 08 | SEC filing · Form 8-K | SEC EDGAR | -1.14% | -0.20% | |
| Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $203 Million | Press release | GlobeNewswire | -1.14% | -0.20% | |
| Form 8-K Ultragenyx Pharmaceutica For: Oct 06 | SEC filing · Form 8-K | SEC EDGAR | +0.14% | +3.04% | |
| Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million | Press release | GlobeNewswire | +0.14% | +3.04% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Ultragenyx Pharmaceutical Inc. (RARE) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.50% | -2.53% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Ultragenyx Pharmaceutical Inc. (RARE) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | -0.21% | +0.48% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Ultragenyx Pharmaceutical Inc. (RARE) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | -0.03% | -2.03% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Ultragenyx Pharmaceutical Inc. (RARE) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.04% | +8.21% | |
| Form 8-K Ultragenyx Pharmaceutica For: Sep 17 | SEC filing · Form 8-K | SEC EDGAR | +0.97% | +0.97% | |
| Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA) | Press release | GlobeNewswire | -0.52% | +0.10% | |
| Ultragenyx Pharmaceutical Inc. (RARE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.30% | -1.21% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Ultragenyx Pharmaceutical Inc. (RARE) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.07% | +0.28% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Ultragenyx Pharmaceutical Inc. (RARE) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.24% | +0.35% | |
| Form 8-K Ultragenyx Pharmaceutica For: Sep 02 | SEC filing · Form 8-K | SEC EDGAR | +0.50% | +6.30% | |
| Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome | Press release | GlobeNewswire | +0.50% | +6.30% | |
| Ultragenyx Announces the Publication of a Successful 96-Week Randomized, Placebo-Controlled Trial with Crossover Treatment of GENGLYCOS™ (also known as DTX401) AAV Gene Therapy in GSDIa in The Journal of Inherited Metabolic Disease | Press release | GlobeNewswire | +2.43% | +2.27% | |
| Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.34% | +0.76% | |
| Form 8-K Ultragenyx Pharmaceutica For: Aug 19 | SEC filing · Form 8-K | SEC EDGAR | -4.01% | -11.00% | |
| Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa) | Press release | GlobeNewswire | -4.01% | -11.00% | |
| Form 8-K Ultragenyx Pharmaceutica For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | -1.03% | -0.74% | |
| Form 10-Q Ultragenyx Pharmaceutica For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -4.99% | -10.84% | |
| Form 8-K Ultragenyx Pharmaceutica For: Aug 04 | SEC filing · Form 8-K | SEC EDGAR | -4.99% | -10.84% | |
| Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update | Press release | GlobeNewswire | -4.99% | -10.84% | |
| Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update | Press release | GlobeNewswire | +0.93% | -2.99% | |
| Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.11% | -1.75% | |
| Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact | Press release | GlobeNewswire | -1.32% | -1.62% | |
| Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +2.24% | +4.80% | |
| Form S-8 Ultragenyx Pharmaceutica | SEC filing · Form S-8 | SEC EDGAR | -0.14% | +0.10% | |
| Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference | Press release | GlobeNewswire | +1.09% | +3.55% | |
| Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.72% | -2.03% | |
| Form 8-K Ultragenyx Pharmaceutica For: May 14 | SEC filing · Form 8-K | SEC EDGAR | -0.23% | -0.41% | |
| Form 10-Q Ultragenyx Pharmaceutica For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.24% | +0.08% | |
| Ultragenyx to Participate at Bank of America’s 2026 Healthcare Conference | Press release | GlobeNewswire | -1.38% | +0.46% | |
| Form 8-K Ultragenyx Pharmaceutica For: May 05 | SEC filing · Form 8-K | SEC EDGAR | +1.24% | +0.08% | |
| Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update | Press release | GlobeNewswire | +1.24% | +0.08% | |
| Form DEFA14A Ultragenyx Pharmaceutica | SEC filing · Form DEFA14A | SEC EDGAR | -0.38% | -0.52% | |
| Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update | Press release | GlobeNewswire | +1.43% | +0.21% | |
| Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.99% | -0.66% | |
| Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RARE | Press release | PR Newswire | +0.49% | +1.87% | |
| DEADLINE NEXT WEEK: Berger Montague Advises Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Investors to Contact the Firm Before April 6, 2026 | Press release | PR Newswire | +0.49% | +1.87% | |
| Form 8-K Ultragenyx Pharmaceutica For: Apr 02 | SEC filing · Form 8-K | SEC EDGAR | +0.43% | +6.65% | |
| Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) | Press release | GlobeNewswire | +0.43% | +6.65% | |
| Form 8-K Ultragenyx Pharmaceutica For: Mar 30 | SEC filing · Form 8-K | SEC EDGAR | +0.15% | -0.92% | |
| Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy | Press release | GlobeNewswire | +0.15% | -0.92% | |
| Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RARE | Press release | PR Newswire | +0.15% | -0.92% | |
| Form ARS Ultragenyx Pharmaceutica For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.15% | -0.92% | |
| Form DEF 14A Ultragenyx Pharmaceutica For: May 14 | SEC filing · Form DEF | SEC EDGAR | +0.15% | -0.92% | |
| Form DEFA14A Ultragenyx Pharmaceutica | SEC filing · Form DEFA14A | SEC EDGAR | +0.15% | -0.92% | |
| Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.15% | +1.00% | |
| Form 8-K Ultragenyx Pharmaceutica For: Mar 12 | SEC filing · Form 8-K | SEC EDGAR | -1.55% | -1.00% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the RARE section they belong to.
Where else RARE is measured.
RARE earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Quotient Limited - Ordinary Shares (QTNT) | 982 | -0.13% | 42% |
| PDL BIOPHARMA (PDLI) | 967 | 0.00% | 46% |
| QuidelOrtho Corporation (QDEL) | 965 | +0.02% | 50% |
| Recro Pharma, Inc. (REPH) | 965 | 0.00% | 43% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Ultragenyx Pharmaceutical Inc.'s median reaction calculated?
Every labeled RARE news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 967 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 56% of RARE's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does RARE's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.